Click here to view the History of Cambrex in PDF format.

2008	Cambrex expanded their group of world class chemists by acquiring Prosyntest in January, now called Cambrex Tallinn.  Steven M. Klosk was appointed as the new CEO while remaining President.
2007	Cambrex exits the biologics market and divests their bio business to Lonza. Cambrex focuses on core competencies utilizing our three manufacturing facilities: Cambrex Karlskoga, Cambrex Profarmaco, and Cambrex Charles City
2006	James Mack was reappointed as CEO from his retirement in 2004.
2003	The company is dedicated to providing essential products and services that accelerate drug discovery, development and the manufacturing of human therapeutics.
2002	To support the Company's strategic emphasis on the growing opportunities in the life sciences industry, Cambrex launches a new corporate identity.
2001	Cambrex enters the biologics market with the acquisition of two contract biopharmaceutical manufacturing facilities. The facilities produce purified bulk biologics and pharmaceutical ingredients from clinical to commercial scale.
1999	Cambrex enters the growing fields of molecular biology and proteomics through the acquisition of FMC Corporation's bioproducts business and adds APIs and six to seven years sold for healthy premium advanced intermediates capacity.
1998	Cambrex acquires a chiral enzymatic catalyst business, a key pharmaceutical technology and a bioscience products facility in Belgium. The Company stock is listed on the NYSE.
1997	Cambrex enters the biosciences market with the acquisition of  a life sciences company providing cell culture and endotoxin detection products.
1994	Cambrex further penetrates the pharmaceutical market with the acquisition of the Nobel Pharma Chemistry business, Nobel Chemicals, AB to Cambrex Karlskoga AB and Profarmaco S.r.l to Cambrex Profarmaco.
1991	The Company enters the life sciences arena with the acquisition of a company that produces animal feed additives and active pharmaceutical ingredients (APIs).
1990	Cambrex is listed on the American Stock Exchange (AMEX).
1987	The Company name changes to Cambrex Corporation. Cambrex is listed on NASDAQ.
1981	The company is founded and CasChem group acquires the castor oil and derivatives  product lines from NL Industries.